The purpose of this study was to find patterns in how etanercept (a medication) is used to treat juvenile idiopathic arthritis (JIA). For more than 20 years, etanercept (also called Enbrel®) has been useful in treating many types of JIA. Many doctors in the US use Enbrel to treat JIA, but it is not known when or how often it is used. This study looked at 2,032 patients with JIA enrolled in the CARRA Registry who were treated with Enbrel. Not all patients with JIA were treated with Enbrel. Following patients in the registry allowed researchers to learn more about how, when, and why doctors use Enbrel to treat JIA patients.
Researchers found many patterns in how doctors used Enbrel (AMGEN) as part of the treatment plan for JIA. Often, doctors prescribed one or more different medicines to treat JIA. In this study, researchers found that doctors often prescribed Enbrel in combination with methotrexate. Enbrel was given to most patients after a short time on methotrexate (about a few weeks or months later).
Among patients who were treated with Enbrel, researchers also found the following patterns of Enbrel use:
This study was able to find several patterns in Enbrel use. But there is more to learn. For example, researchers and families hope to learn more about when and how doctors decide to lower or stop Enbrel use for patients whose arthritis is doing well. Doctors are also curious to know which patients respond best to Enbrel treatment compared to other available medications. Future studies like this can use the CARRA Registry to help doctors provide better care for patients with JIA and other rheumatic diseases.
Learn more about what other CARRA research projects are finding from their work.
View the full contents of this article to learn more about patterns in Enbrel use for treatment of JIA patients.
This study was supported by Amgen Pharmaceuticals.